Wall Street brokerages expect Moleculin Biotech Inc (NASDAQ:MBRX) to report earnings per share (EPS) of ($0.09) for the current quarter, according to Zacks. Zero analysts have issued estimates for Moleculin Biotech’s earnings. Moleculin Biotech reported earnings per share of ($0.10) during the same quarter last year, which suggests a positive year-over-year growth rate of 10%. The company is expected to announce its next earnings report on Tuesday, November 12th.
On average, analysts expect that Moleculin Biotech will report full year earnings of ($0.37) per share for the current fiscal year. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Moleculin Biotech.
Moleculin Biotech (NASDAQ:MBRX) last posted its earnings results on Friday, August 16th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.07.
NASDAQ MBRX traded down $0.04 on Friday, reaching $1.13. The company had a trading volume of 102,740 shares, compared to its average volume of 219,432. The firm has a market capitalization of $52.88 million, a PE ratio of -2.22 and a beta of 2.03. Moleculin Biotech has a 1 year low of $0.78 and a 1 year high of $3.15. The firm has a 50-day moving average of $1.15 and a 200-day moving average of $1.21. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.11 and a quick ratio of 1.49.
Several institutional investors have recently added to or reduced their stakes in the company. Morgan Stanley boosted its stake in shares of Moleculin Biotech by 151.7% during the 2nd quarter. Morgan Stanley now owns 31,411 shares of the company’s stock valued at $39,000 after buying an additional 18,933 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Moleculin Biotech by 109.1% during the 4th quarter. Northern Trust Corp now owns 47,918 shares of the company’s stock valued at $50,000 after buying an additional 25,000 shares during the last quarter. Taylor Cottrill Erickson & Associates Inc. boosted its stake in shares of Moleculin Biotech by 24.6% during the 1st quarter. Taylor Cottrill Erickson & Associates Inc. now owns 151,781 shares of the company’s stock valued at $123,000 after buying an additional 30,000 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Moleculin Biotech during the 4th quarter valued at approximately $36,000. Finally, BB&T Corp boosted its stake in shares of Moleculin Biotech by 55.6% during the 1st quarter. BB&T Corp now owns 140,000 shares of the company’s stock valued at $113,000 after buying an additional 50,000 shares during the last quarter. Institutional investors own 6.49% of the company’s stock.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
Featured Article: What does the Producer Price Index (PPI) tell investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.